In Brief
It is unclear how quiescence is enforced in naive T cells, yet activation is allowed. Tu et al. show that TGF-b signaling maintains T cell quiescence. Strong TCR stimuli reduce TbRI expression and consequently abolish TGF-b signaling in T cells. TCR-mediated TbRI downregulation acts as a ''third criterion'' to fully activate T cells in addition to the ''two-signal'' model.
INTRODUCTION
The initiation and magnitude of the T cell response is dependent on the balance of stimulatory and inhibitory signals. Naive T cells are present in blood and peripheral lymphoid organs in their quiescent state, characterized by small cell size and reduced metabolic activity. The quiescent state of naive T cells was thought to occur by default due to the lack of activation signals. However, accumulating studies have shown that survival of naive T cells in the steady state requires T cell receptor (TCR) tickling by self-MHC (major histocompatibility complex) molecules (Takada and Jameson, 2009 ). TCR tickling does not lead to autoimmunity in healthy individuals, as T cell quiescence is actively enforced by extrinsic factors such as regulatory T (Treg) cells and intrinsic mechanisms such as transcription factors Peli1 (pellino1), TRIM28 (tripartite motif-containing protein 28), Foxp1 (forkhead box P1), Tsc1 (tuberous sclerosis 1), and Tob (Chang et al., 2011; Chikuma et al., 2012; Feng et al., 2011; Sakaguchi et al., 2008; Tzachanis et al., 2001; Yang et al., 2011) .
However, a few unresolved issues have arisen from these studies. First, it is not understood how T cell activation can still occur upon antigen stimulation when these mechanisms are in place to maintain T cell quiescence and tolerance. The ''twosignal'' model of T cell activation has been widely accepted: the first signal provided by the engagement of TCRs to peptide-MHC complexes on antigen-presenting cells (APCs) and the second signal provided by costimulation (Smith-Garvin et al., 2009) . It is plausible that an additional signal is required to release T cells from quiescence programs to achieve T cell activation. Second, although hyperactivation and hyperproliferation of T cells were observed in mice with deletion of any of the quiescence-associated factors, none of these mice developed early-onset lethal autoimmune diseases like mice with deficiency in Foxp3, cytotoxic T lymphocyte-associated protein 4 (CTLA-4), or transforming growth factor b (TGF-b) (Fontenot et al., 2003; Hori et al., 2003; Shull et al., 1992; Waterhouse et al., 1995) . However, Foxp3 and CTLA-4 are unlikely to regulate quiescence in naive T cells intrinsically, as they are not expressed in naive T cells (Egen and Allison, 2002; Josefowicz et al., 2012) . These findings collectively suggest that there must be other mechanism(s) that play a major role in governing quiescence of naive T cells, and TGF-b signaling is one such candidate.
TGF-b is involved in the development, survival, and function of various immune cells, especially T cells (Tu et al., 2014) . Bioactive TGF-b binds to TGF-b type II receptor (TbRII) and induces the assembly of a tetrameric TGF-b receptor complex (TbR) composed of TbRII and TbRI, which phosphorylates the transcription factors mothers against decapentaplegic (SMAD)2 and SMAD3. Phosphorylated SMAD2 and/or SMAD3 form complexes with SMAD4 and are translocated into the nucleus, where they associate with DNA-binding cofactors to regulate the transcription of target genes (Shi and Massagué , 2003) . In addition, SMAD-independent pathways are also involved in mediating TGF-b signaling (Derynck and Zhang, 2003) . The roles of TGF-b in suppressing activation of T cells have been well demonstrated by either addition of exogenous TGF-b to T cells in vitro (Ruegemer et al., 1990) or by genetic mutation of TGF-b ligands or receptors in T cells (Li et al., 2006; Liu et al., 2008; Marie et al., 2006; Shull et al., 1992) . However, few studies have investigated the impact and mechanisms of TCR stimulation in TGF-b signaling and the consequential effects on the balance between T cell quiescence and T cell activation.
Here, we show that active TGF-b signaling is present in naive T cells, and strong TCR stimulation abolishes TGF-b signaling to overcome its ongoing inhibition, through downregulation of TbRI expression. TbRII did not play an important role in the process. Accordingly, overexpression of TbRI in naive T cells and restoration of TbRI in activated T cells constrained T cell responses. TCR stimulation drove the downregulation of TbRI through activation of the caspase recruitment domain-containing protein 11 (CARD11) and nuclear factor kB (NF-kB) pathway. We demonstrated that TbRI expression was significantly lower in naive CD4 + T cells of systemic lupus erythematosus (SLE) patients compared to healthy subjects. These results reveal a TCR-NFkB-TbRI axis that acts as a switch between T cell quiescence and T cell activation.
RESULTS

TCR Signals Downregulate TGF-b Signaling and TbR Expression in Naive T Cells
We first examined TGF-b signaling in naive CD4 + T cells isolated from normal mice and humans. The amount of phosphorylated SMAD2 (p-SMAD2) protein was used as a readout for the degree of TGF-b signaling in T cells, as SMAD2 is phosphorylated when TbR is activated by TGF-b. Freshly isolated naive CD4 + T cells (0 hr) exhibited p-SMAD2 protein, indicating the presence of active TGF-b signal in naive CD4 + T cells ( Figure 1A ). We next stimulated naive CD4 + T cells in vitro with anti-CD3 and anti-CD28 to determine TGF-b signaling during T cell activation. We found that the amount of p-SMAD2, but not total SMAD2, protein decreased rapidly when T cells were activated ( Figure 1A) . A similar phenomenon was observed when human naive and/or resting CD4 + T cells were stimulated ( Figure 1A ). To exclude the possibility that the reduction of p-SMAD2 in TCR-stimulated T cells might be caused by lack of sufficient amounts of TGF-b in cultures, we treated naive and previously activated (24 hr stimulation) T cells with a high concentration of TGF-b (2 ng/mL). We still detected higher levels of p-SMAD2 in naive T cells than in TCR-activated T cells in the presence of exogenous TGF-b, indicating an intrinsic feature of TCR stimulation in reducing TGF-b signals ( Figure 1B) . These results altogether indicate that active TGF-b signaling is present in naive T cells but is reduced during T cell activation. We next examined the components of the TGF-b signaling pathway affected upon TCR stimulation. We showed that activation of naive CD4 + T cells by anti-CD3 and anti-CD28 led to downregulation of TbRI and TbRII mRNA expression. This was observed in both mouse ( Figure 1C ) and human ( Figure 1D ) CD4 + T cells, as well as in mouse CD8 + T cells (data not shown). There was a time dependency in TbRI and TbRII downregulation, as indicated by much lower TbRI and TbRII expression in T cells that received prolonged stimulation (24 hr) than T cells that received short stimulation (1 hr). The downregulation of TbRI and TbRII was ascribed to TCR signals since stimulation of naive CD4 + T cells with anti-CD3 alone was sufficient to induce the downregulation ( Figure 1E ), whereas stimulation with anti-CD28 alone did not cause TbR downregulation (data not shown).
We further demonstrated downregulation of TbRI and TbRII in T cells activated in vivo by challenging DO11.10 TCR transgenic mice with OVA (ovalbumin) peptide that was specifically recognized by T cells in these mice, in which downregulation of TbRI and TbRII correlated with interleukin (IL)-2 mRNA upregulation ( Figure 1F ). Thus, TCR stimulation downregulates TbRI and TbRII transcription in naive CD4 + T cells.
We next investigated whether TbRI and TbRII proteins were also regulated by TCR signals. We showed that TCR stimulation reduced the amount of TbRI protein ( Figure 1G ). However, the level of TbRII protein was not affected by TCR stimulation ( Figure 1G ), despite reduced TbRII mRNA expression. The data indicate that the reduction of TbRI, but not TbRII, correlates with the downregulation of TGF-b signaling in T cells upon T cell activation.
Strength of TCR Stimuli Determines TbRI Expression
As the change in TbRI reflects the change in TGF-b signaling upon TCR stimulation, we next sought to determine the effect of TCR stimulation strength on TbR expression. When naive T cells were stimulated with different concentrations of anti-CD3, it was evident that the degree of TbRI and TbRII downregulation was regulated by the strength of TCR signals, with a high (E) Tgfbr1 and Tgfbr2 mRNA in naive CD4 + T cells stimulated for 24 hr with anti-CD3 plus anti-CD28 or anti-CD3 alone.
(F) IL-2, Tgfbr1, and Tgfbr2 mRNA in T cells from DO11.10xRag2 À/À mice treated with PBS (Ctrl) or OVA peptide (pOVA).
(G) Western blot of TbRI, TbRII, and GAPDH in naive or CD4 + T cells stimulated for 24 hr with anti-CD3 and anti-CD28.
(H) Tgfbr1 and Tgfbr2 mRNA in naive CD4 + T cells stimulated for 24 hr with 1 mg/mL anti-CD28 plus indicated concentration of anti-CD3.
(I) Tgfbr1 and Tgfbr2 mRNA in T cells from DO11.10xRag2 À/À mice treated with indicated doses of pOVA.
(J) Tgfbr1 and Tgfbr2 mRNA in naive 5CC7 T cells cultured for 24 hr with APCs and indicated peptides. Data are pooled from two (D and I), three (C, F, H, and J), or four (B and E) independent experiments or are representative of three (A and G) independent experiments. In (F) and (I), each circle represents the data from one mouse. Student's t test was used. Bars, mean; error bars, SD; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. See also Figure S1 .
concentration of anti-CD3 causing more TbRI and TbRII mRNA downregulation ( Figure 1H ). In contrast, weak TCR stimulation (e.g., 0.01 mg/mL anti-CD3) failed to reduce and, instead, upregulated TbRI and TbRII expression compared to naive T cells. The strength of TCR signals also had a similar effect on TbRI and TbRII expression in vivo when DO11.10 T cells were stimulated with different doses of OVA peptide ( Figure 1I ). Furthermore, we showed that the TCR affinity to antigens also differentially regulated the expression of TbR. When 5CC7 TCR transgenic T cells were stimulated with their natural ligand moth cytochrome C (MCC) or the superagonist K5 (Krogsgaard et al., 2003) , significantly lower TbRI and TbRII expression was detected than in 5CC7 T cells stimulated with weak agonist peptide, 102S ( Figure 1J ). We also extended this finding to CD8 + T cells by stimulating OT-I TCR transgenic T cells with OVA peptide variants (Daniels et al., 2006 ). Significant T cell activation and TbRI downregulation were detected when OT-I T cells were stimulated with their high-affinity cognate antigen, N4 peptide (Figures S1A and S1B) . In comparison, T4 peptide, which has intermediate affinity for OT-I TCR, induced T cell activation and TbRI downregulation only at a high dose, and the weak peptide E1 was unable to induce TbRI downregulation even at a high dose. As TbRI expression in T cells negatively correlated with the strength of TCR stimuli, we hypothesized that strength of TCR stimuli could regulate T cell differentiation, especially the T cell subsets that require TGF-b for their generation (Tu et al., 2014) . We adoptively transferred naive 5CC7 T cells to the syngeneic B10.A mice and challenged the mice with MCC peptide (pMCC) at different doses ( Figure 2A ). Consistent with our findings in vitro, low-dose pMCC (0.1 mg) stimulation led to a higher TbRI expression in 5CC7 T cells than did highdose (10 mg) ( Figure 2B ), whereas TbRII was not affected regardless of dose. Low-dose antigen stimulation also induced a higher frequency of Foxp3 + Treg cells, but a lower frequency of IFNg-producing T helper (Th)1 cells, compared to high-dose antigen stimulation ( Figures 2C and 2D) . In contrast, a high dose of pMCC led to more Th1 cells but fewer Treg cells (Figures 2C and 2D) . We next investigated if reduction of TbRI expression with a high dose of antigen stimulation could affect Th17 cell differentiation in vivo. When 5CC7 T cells were challenged with a high dose (10 mg) or a low dose (0.1 mg) of pMCC with complete Freund's adjuvant (CFA), a decrease in TbRI, but not TbRII, was observed in high-dose antigen-challenged transgenic T cells compared to low-dose antigen-challenged T cells ( Figure 2E ). Indeed, an increase in the frequency of Th17 cells in these T cells correlated with decreased TbRI expression in T cells that were challenged with a high dose of pMCC ( Figure 2F ). These data altogether indicate that the strength of TCR stimulation regulates TbRI expression, which correlates with T cell lineage decisions.
TCR Signals Downregulate TbRI Expression through the NF-kB Pathway TCR-mediated downregulation of TbR was likely to depend on transcriptional regulation since both total and nascent TbRI and TbRII mRNA were significantly lower in activated T cells than in naive T cells ( Figure 3A) . We next investigated the underlying molecular mechanisms by which TCR signals regulate TbR expression. SMAD7 has been previously reported to act as an inhibitor for TGF-b signaling and TbR expression in epithelial cells and cancer cell lines (Nakao et al., 1997) . However, we found that CD4 + T cells from Smad7 f/f Cd4-cre and Smad7
Cd4-cre mice showed similar degrees of TbR downregulation upon TCR activation ( Figure S2A ), suggesting non-involvement of SMAD7. Furthermore, TGF-b signaling in T cells was not significantly affected by the absence of SMAD7 when T cells were stimulated in the presence or absence of TGF-b (Figure S2B) . Thus, downregulation of TbR during T cell activation is independent of SMAD7. Given that downregulation of TbRI is mediated by TCR signals, it is likely that transcription factors that are downstream of TCRs act as repressors for TbRI expression during T cell activation. Indeed, predicted binding sites for transcription factors, such as NF-kB and nuclear factor of activated T cells (NFAT), were detected in the promoter region of TbRI using bioinformatics tools (BIOBASE, ALGGEN-PROMO). NF-kB and NFAT play important roles in TCR signaling (Smith-Garvin et al., 2009) . As expected, we found that chemical inhibitors for NF-kB (IKK [IkB kinase] inhibitor VII) and NFAT (cyclosporin A) were both able to suppress the upregulation of IL-2 mRNA in activated T cells. However, only NF-kB inhibition prevented TCR-mediated TbRI downregulation, but not inhibition of NFAT ( Figure 3B ). Neither NF-kB nor NFAT inhibitors had any effect on the downregulation of TbRII mRNA induced by TCR stimulation ( Figure 3B ). Despite not finding any transcription factor that regulates TbRII mRNA during T cell activation, we found that TCR signals significantly accelerated TbRII mRNA decay ( Figure S3A ), providing a possible mechanism for TCR-mediated TbRII mRNA downregulation.
We further confirmed the role of NF-kB as the repressor of TbRI expression using T cells from Card11 À/À mice and NfkbiaDN-Tg mice. The NF-kB pathway is inhibited in T cells from Card11 À/À mice since TCRs mediate NF-kB activation through CARD11 (Egawa et al., 2003) . NfkbiaDN-Tg mice express, selectively in T cells, a super-repressor form of IkBa, which constitutively inactivates NF-kB (Boothby et al., 1997) . Naive CD4 + T cells from Card11 À/À and NfkbiaDN-Tg mice did not show downregulation of TbRI expression after TCR stimulation ( Figure 3C ). Inhibition of NF-kB activity in Card11 À/À and NfkbiaDN-Tg mice could not rescue TbRII mRNA during T cell activation ( Figure 3C ). We next determined which NF-kB subunits were required for the reduction of TbRI. p50, p52, and cRel were not required for the downregulation of TbRI by TCR signals, as TCR stimulation induced a similar degree of TbRI downregulation in T cells from mice that lacked these NF-kB subunits compared to wild-type mice ( Figure 3D ). As p65 (RelA) deletion is embryonically lethal, we inhibited p65 activity in T cells using caffeic acid phenethyl ester (CAPE) that prevented the translocation of p65 to the nucleus (Natarajan et al., 1996) . CAPE prevented TbRI downregulation in stimulated T cells ( Figure 3E ). Using chromatin immunoprecipitation (ChIP) assays, we also detected significantly higher binding of p65 at the predicted NF-kB binding site in the promoter region of TbRI in activated T cells than in naive T cells ( Figure 3F ). In contrast, there was no significant enrichment of other NF-kB subunits at the same region of TbRI gene in activated T cells ( Figure S3B ). Together, these experiments indicate that NF-kB is essential for TCR-mediated downregulation of TbRI. (E) Tgfbr1 mRNA in naive CD4 + T cells stimulated for indicated time periods with anti-CD3 and anti-CD28 plus DMSO (Control) or CAPE.
(F) ChIP-coupled real-time PCR analysis of p65 enrichment in the promoter region of Tgfbr1 gene of naive or T cells stimulated for 24 hr with anti-CD3 and anti-CD28 (Activated). p65 enrichment was assessed using p65 antibody and presented relative to input and compared with control IgG. Data are pooled from two (A, B, and D), three (E), or four (C) independent experiments or are representative of three (F) independent experiments. In (A), (C), (D), and (F), Student's t test was used. In (B) and (E), two-way ANOVA was used. Bars, mean; error bars, SEM; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. See also Figures S2 and S3.
TGF-b Prevents TCR-Mediated TbRI Downregulation
In addition to TCR stimuli, we also investigated the role of cytokines on TbR expression in CD4 + T cells. We added a panel of cytokines to TCR-stimulated naive CD4 + T cell cultures and determined TbRI and TbRII mRNA expression. Only TGF-b prevented TCR-mediated downregulation of TbRI, but not TbRII mRNA (Figures 4A and 4B) . This was also reflected in TbRI protein levels ( Figure 4C ). In contrast, TbRII protein was detected at similar levels with or without TGF-b ( Figure 4C ). Similarly, TGF-b treatment of naive T cells without TCR stimulation also led to an increase in TbRI, but not TbRII, protein ( Figure S4A ). The TGFb-mediated maintenance of TbRI expression in activated T cells corresponded to substantial amounts of p-SMAD2 in these T cells ( Figure 4D ). We further confirmed the effect of TGF-b on TbRI expression using Tgfbr2
Esr1-cre mice (Nakatsukasa et al., 2015) . These mice express a mutated form of the mouse estrogen receptor, and administration of tamoxifen induces efficient cre-mediated deletion of TbRII. T cells that were deficient in TbRII failed to upregulate their TbRI expression when stimulated in the presence of TGF-b ( Figure 4E ). We also determined that the upregulation of TbRI by TGF-b was, in part, through a SMAD-dependent pathway. ). Indeed, a significantly higher level of TbRI was detected in Treg cells than in non-Treg cells before and after anti-CD3 and anti-CD28 stimulation. However, lower TbRII expression was detected in freshly isolated Treg cells, and no subsequent changes occurred upon TCR stimulation ( Figure 4G ). Overall, these data indicate that TCR-mediated reduction of TbRI is prevented by TGF-b.
IL-6 Abolishes TGF-b-Mediated Prevention of TbRI Reduction
As cytokines alone (with the exception of TGF-b) did not influence TCR-mediated TbRI downregulation in naive T cells (Figure 4A) , we next investigated whether proinflammatory cytokines could interfere with the effect of TGF-b on TbRI expression. We stimulated naive CD4 + T cells with anti-CD3 and anti-CD28 in the presence of both TGF-b and proinflammatory cytokines: IL-1b, IL-2, IL-4, IL-6, IL-12, IL-23, IFNg, and TNF-a. Only IL-6 blocked the upregulation of TbRI by TGF-b ( Figure S4B ; data not shown). However, IL-6 had no effect on TbRII expression ( Figure S4B ). We further confirmed the inhibitory effects of IL-6 on TGFb-mediated TbRI upregulation in vivo. Since bacteria antigens in CFA enhance IL-6 production in innate immune cells, we analyzed myelin oligodendrocyte glycoprotein (MOG)-specific T cells in mice that were immunized with MOG peptide with either CFA or incomplete Freund's adjuvant (IFA) ( Figure S4C ). The hypothesis was that IL-6 induced by CFA would reduce TbRI levels in MOG-specific T cells, compared to T cells from IFA-treated mice that received the same TCR stimulation in a TGF-b-present microenvironment. Indeed, MOG-specific T cells in mice treated with MOG and CFA showed lower TbRI, but not TbRII, expression than T cells in mice treated with MOG and IFA ( Figure S4D ). MOG and CFA also increased IL-17 production in MOG-specific T cells ( Figure S4E ), consistent with the previous notion that reduction of TGF-b signaling favors Th17 cell differentiation (Zhou et al., 2008) . These results suggest that IL-6 may affect TGF-b signaling in T cells by antagonizing the effect of TGF-b on TbRI expression.
TbRI Downregulation Promotes T Cell Responses
We next determined the effect of TCR-mediated downregulation of TbRI on T cell responses. Since the majority of T cells are hyperactivated in T cell-specific TbR-deficient mice, we used naive CD4 + T cells from Tgfbr1 f/f Esr1-cre mice to address this question. Similar CD4 + T cell frequencies were detected in the lymphoid organs of Tgfbr1
Esr1-cre mice and wild-type mice, and TbRI was deleted in Tgfbr1 f/f Esr1-cre mice upon completion of tamoxifen treatment (data not shown). Naive CD4 + T cells from tamoxifen-treated Tgfbr1 f/f Esr1-cre mice (Tam) and untreated control Tgfbr1 f/f Esr1-cre mice (Ctrl) were cultured with different concentrations of soluble anti-CD3 and APCs, and levels of T cell proliferation and IFNg production were measured. In response to TCR stimulation, greater cell proliferation was detected in TbRI-deficient T cells than in control T cells. Furthermore, we detected a greater difference between TbRI-deficient and control T cells when the cells were stimulated with a low concentration of anti-CD3 compared to a high concentration (Figure S5A ). When T cells were stimulated with plate-bound anti-CD3, which provides stronger TCR stimulation than soluble anti-CD3, a difference in cell proliferation between TbRI-deficient and control T cells was only detected when the cells were stimulated with a low, but not a high, concentration of anti-CD3 ( Figure S5B ). This was most likely due to depletion of TbRI in control T cells by strong TCR stimulation. We also detected a similar pattern in IFNg production: weak anti-CD3 stimulation led to a more dramatic difference in IFNg production between TbRI-deficient and control T cells, compared to strong anti-CD3 stimulation ( Figure S5C ). In addition, TbRI-deficient T cells were more resistant to suppression by Treg cells (Figure S5D) , consistent with the findings that TGF-b signaling in responder cells is required for Treg cell-mediated immunosuppression (Fahlé n et al., 2005) . These results demonstrate an increase in the magnitude of the T cell response to TCR stimulation in the absence of TbRI expression. We next investigated whether T cell responses would be affected if we overrode the inherent TbR downregulation by overexpressing TbR in naive T cells. We generated retrogenic mice using bone marrow cells infected with retrovirus for TbRI (legend continued on next page) transgenic expression of TbRI, as TbRI GFP expression was driven by a CMV (cytomegalovirus) promoter that was subject to different regulatory mechanisms compared to the endogenous TbRI. TbRI GFP+ CD4 + T cells showed a significant decrease in IL-2 expression and increase in Foxp3 expression in response to TCR stimulation, even in the absence of exogenous TGF-b ( Figure 5A ), and these changes were further enhanced by TGF-b. Consistently, TbRI GFP+ CD4 + T cells exhibited less proliferation than Ctrl GFP+ CD4
+ T cells when stimulated with anti-CD3
and APCs ( Figure 5B ). In contrast, IL-2 was expressed at a similar level in both TbRII Cherry and Ctrl Cherry T cells upon stimulation ( Figure S6A) .
We also tested the response of these transgenic T cells in vivo using a colitis model based on T cell responses to commensal bacteria in the gut. Rag1 À/À mice that received naive TbRI GFP+ CD4 + T cells were better able to maintain their body weight than mice that received naive Ctrl GFP+ CD4 + T cells, which showed dramatic weight loss ( Figure 5C ), and the severity of colitis in mice was significantly lower in the former group ( Figures  5D and 5E ). Significantly fewer effector CD4 + T cells were detected in mice that received TbRI GFP+ CD4 + T cells than in the controls ( Figure 5F ). More Treg cells were also found in mice that received TbRI Figure S6F ). These data further suggest that it is the level of TbRI, but not TbRII, that determines TGF-b signaling in T cells. Taken together, these depletion and overexpression experiments establish that downregulation of TbRI allows for efficient T cell responses.
Restoration of TbRI in Activated T Cells Reduces T Cell Proliferation
We also investigated the effect of restoration of TbRI expression on activated T cells. Figure 6B ). TbRI GFP+ -DO11.10 T cells were less responsive to challenge with OVA peptide than Ctrl GFP+ -DO11.10 T cells ( Figure 6C ). Conversely, TbRII Cherry had no effect on the proliferative response of activated DO11.10 T cells when challenged with OVA peptide ( Figure S7B ).
When TbRI GFP+ -and TbRII Cherry+ -DO11.10 T cells were tested in a mouse model of airway inflammation ( Figure 6D ), significantly fewer TbRI GFP+ -DO11.10 T cells were found in the lungs and the draining lymph nodes than Ctrl GFP+ -DO11.10 T cells (Figure 6E) . This was consistent with reduced Ki-67 expression in TbRI GFP+ -DO11.10 T cells ( Figure 6F ). Although none of the mice developed prominent pathological changes in their lungs upon completion of intratracheal challenge with OVA protein (data not shown), which was likely due to very low frequencies of both TbRI GFP+ -and Ctrl GFP+ -DO11.10 T cells in the lung tissue, significantly fewer TbRI GFP+ -DO11.10 T cells were found in the lungs ( Figure 6E ). Moreover, we found that restoration of TbRI in activated T cells led to reduced NF-kB activity, as indicated by a decreased level of phosphorylated p65 compared to the control T cells (Figure 6G ), which may account for reduced T cell responses in TbRI GFP+ activated T cells. In contrast, expression of TbRII Cherry did not affect the frequency and proliferation of activated DO11.10 T cells ( Figures S7C and S7D) . These results altogether demonstrate that restoration of TbRI in activated T cells reduced T cell responses to antigens.
TbRI Expression Is Reduced in Naive T Cells of Autoimmune Patients
Since strong TCR stimulation is required for downregulation of TbRI, we hypothesized that there would be a difference in the level of TbRI between healthy individuals and patients with autoimmunity. We tested this hypothesis in recently diagnosed and untreated SLE patients. We detected significantly lower TbRI expression in naive CD4 + CD45RA + T cells from SLE patients than in those from healthy individuals ( Figure 7A ). Consistently, upon anti-CD3 stimulation, naive T cells from SLE patients further reduced their TbRI ( Figure 7A ) and exhibited significantly more proliferation than healthy control T cells ( Figure 7B ). There was an increase in the proliferation of naive T cells from healthy individuals when anti-CD3 stimulation was increased from 1 to 10 mg/mL. However, naive T cells from SLE patients already for 24 hr. Data are pooled from two (A and E-G) or three (B) independent experiments or are representative of three (C and D) independent experiments. In (B), (E), and (F), two-way ANOVA was used. In (G), Student's t test was used. Bars, mean; error bars, SD in (A) and (E)-(G) and SEM in (B); *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. See also Figure S4 .
reached the plateau for proliferation at a low concentration of anti-CD3 (1 mg/mL) and failed to proliferate further when simulated with a high concentration (10 mg/mL) ( Figure 7B ), indicating a significant decrease in TCR signaling threshold in SLE naive T cells. Thus, the data suggest that intrinsic differences such as TbRI expression in naive T cells between healthy individual and autoimmunity patients may contribute to increased T cell responses. Data are pooled from two (A and B) or three (C-G) independent experiments. In (D), (F), and (G), each circle represents the data from one mouse. In (A), (B), (D), (F), and (G), Student's t test was used. In (C), two-way ANOVA was used. Bars, mean; error bars, SD in (A) and (B) and SEM in (C); *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. See also Figures S5 and S6 .
deletion of TbR exhibit systemic T cell activation and responses (Li et al., 2006; Liu et al., 2008; Marie et al., 2006) . It was unclear how T cells achieve T cell activation despite the omnipresence of TGF-b in tissues and blood. We showed that strong TCR stimulation induced downregulation of TbRI, which reduced sensitivity of T cells to TGF-b. Furthermore, TCR-mediated downregulation of TbRI is essential for T cells to induce optimal T cell responses, as evidenced by the data from TbRI-overexpressing retrogenic mice, as well as restoration of TbRI expression in activated T cells. Therefore, our results demonstrate that in addition to the two signals that are required for T cell activation, TCR-mediated downregulation of TbRI acts as a ''third criterion'' for T cells to achieve the full array of immune responses. When naive CD4 + T cells were TCR stimulated, a significant decrease in TbRI expression was observed in both mRNA and protein levels, which was associated with reduction in TGF-b signaling in activated T cells. Despite a rapid decrease in TbRII mRNA during T cell activation, the amount of TbRII protein surprisingly remained relatively unchanged in activated T cells. Although we found that TCR signals accelerated decay of TbRII mRNA, this did not lead to a decrease in the protein level. One possibility of this non-correlation may be the long half-life of TbRII protein in T cells, but this remains to be elucidated. Alternatively, it is possible that we detected the decrease in TbRII mRNA during a short window of time when it was transiently downregulated. Indeed, significant downregulation of TbRI and TbRII mRNA was seen in T cells that were stimulated in vivo for 24 hr by strong antigen stimulation. However, only the reduction of TbRI, but not TbRII, mRNA was detected seven days after stimulation, suggesting that the change in TbRII mRNA is not sustained.
Our data also strongly suggest that TbRI and TbRII might be fundamentally different with regard to their correlation with TGF-b signaling in T cells. Previous studies showed that both TbRI and TbRII were important in TGF-b-mediated T cell tolerance since mice with T cell-specific deletion of either TbRI or TbRII die from lethal autoimmune disease (Li et al., 2006; Liu et al., 2008; Marie et al., 2006) . This was expected, as TbRII is required to bind to TGF-b ligands and then activates TbRI. However, multiple lines of evidence show that TbRI plays a more important role than TbRII in TCR-mediated downregulation of TGF-b signaling: (1) TbRI protein, but not TbRII protein, was reduced upon TCR stimulation; (2) no difference in colitis severity was seen between mice that received TbRII Cherry -overexpressing naive T cells and those that received control T cells, whereas naive T cells overexpressing TbRI GFP were unable to induce severe colitis; (3) mice that received TbRI GFP+ T cells, but not mice that received TbRII Cherry+ T cells, displayed increased Treg cell frequencies; and (4) restoration of TbRI alone in activated T cells was sufficient to reduce T cell proliferation upon antigen challenge, whereas TbRII overexpression had no effect. Although mechanistically elusive, these results do suggest that TbRI serves as the accurate reflection of TGF-b signaling that controls the development of T cell responses. This conclusion, however, does not eliminate a role for TbRII in TGF-b signaling; it only suggests that the changes in levels of TbRII do not reflect and control TGF-b signaling in T cells in response to TCR stimulation. A recent study on the conversion of natural killer (NK) cells into type 1 innate lymphoid cells (ILC1s) has indicated that TbRI can achieve TGF-b signaling independently of TbRII, in these cells (Cortez et al., 2017) . However, the non-redundant role of TbRII in TGF-b signaling in T cells has been shown by other groups (Li et al., 2006; Marie et al., 2006) . Thus, it is likely that TbR and its downstream targets may function differently among different immune cell subsets. We found that TbRI expression is tightly regulated by the strength of TCR stimulation. T cells that were stimulated with weak or low-dose TCR stimuli showed no reduction and, very likely, higher TbRI expression compared to naive T cells. In marked contrast, T cells that were activated with strong or high-dose TCR stimuli exhibited rapid and profound reduction of TbRI compared to naive T cells. This finding has important implications for understanding the quiescence program and general lack of autoimmunity in healthy individuals, despite the existence of self-reactive T cells that regularly encounter self-antigens. Moreover, our findings may help reconcile how T cell quiescence is maintained while T cell activation and proliferation are allowed during encounter with pathogens, even in the presence of TGF-b. Low levels of active TGF-b in blood and tissues are normally sufficient to prevent unwanted T cell response to self-antigens, despite the fact that the majority of TGF-b is present in a latent form. This is because, following establishment of central and peripheral tolerance, T cells that are normally present in the body recognize self-antigens with low affinity. ''Tickling'' by low-affinity self-antigens is not sufficient to induce TbRI downregulation and allows for ongoing TGF-b signaling. On the other hand, engagement of TCRs with high-affinity antigens or foreign antigens is able to induce TbRI downregulation and promote T cell responses. This was demonstrated when N4 peptide induced T cell activation and TbRI downregulation in OT-I T cells, whereas E1 peptide was not able to induce TbRI downregulation, even at a high peptide dose. It was previously shown that E1 peptide induced positive selection of OT-I thymocytes (Daniels et al., 2006) , and we show in our experiments that this peptide did not induce T cell activation and TbRI downregulation in peripheral OT-I T cells, which reflects the interaction between naive T cells and self-antigens. Thus, in addition to the amount of endogenous TGF-b in the environment, the strength of TCR stimulation also determines the inhibitory effects of TGF-b on T cells. Given that TGF-b signaling in T cells is essential for Treg cell generation, our data may also explain the phenomenon that weak TCR stimulation favors the generation of Treg cells (Gottschalk et al., 2010) . We found higher TbRI expression in T cells, greater Treg cell frequencies, and lower Th1 and Th17 frequencies in mice that received low-dose antigen stimulation than in those that received high-dose.
The findings in this study may provide an explanation as to why activated T cells are more resistant to suppression by Treg cells compared to naive T cells (Korn et al., 2007; Tu et al., 2013) . It can be envisioned that TbRI downregulation in activated T cells contributes to their resistance to Treg cells. Supporting this notion, we have shown that T cells that lack TbRI are more resistant to Treg cell suppression. Furthermore, our findings may provide insight as to why Treg cells are much more effective in preventing the development of autoimmunity than in treating ongoing diseases (Tu et al., 2013) . Since pathogenic T cells in ongoing autoimmunity are already activated by autoantigens, reduced TbRI expression and TGF-b signaling in these T cells may render Treg cells ineffective. Our finding that TGF-b prevents TCR-mediated TbRI downregulation in T cells has important implications for our understanding of the development and pathogenesis of autoimmunity and cancer. The preservation and even upregulation of TbRI by TGF-b present in blood and tissues may be critical in enforcing quiescence in naive T cells and preventing T cells from abnormal activation in response to TCR stimulation, thus avoiding autoimmunity. This may also account for insufficient anti-tumor T cell responses in tumor patients, despite the presence of tumor antigen-specific T cells within tumors. Since TGF-b is produced in large amounts in the tumor microenvironment, TGF-b may inhibit anti-tumor immunity by upregulation of TbRI in T cells, thereby increasing their threshold for T cell activation. This conclusion is supported by previous studies that demonstrate anti-tumor immunity and tumor clearance after reduction of TGF-b signaling in T cells (Gorelik and Flavell, 2001; Thomas and Massagué , 2005) . Furthermore, poor immunogenicity of tumor antigens may further impede anti-tumor responses since weak antigen stimulation does not induce TbRI downregulation, especially in the presence of substantial amounts of TGF-b. Therapeutic strategies to deliver strong antigen stimulation to downregulate TbRI expression in T cells may be critical in achieving better anti-tumor immunity.
We have recently shown that TGF-b signaling to Treg cells is required for Treg cell activity (Konkel et al., 2017) , which suggests that Treg cells rely heavily on TGF-b for the maintenance of their phenotype. This may be facilitated by the high expression of TbRI in Treg cells. Furthermore, Treg cells express higher levels of membrane-bound TGF-b compared to non-Treg cells (Nakamura et al., 2001) , and it is possible that membrane-bound TGF-b is required to keep Treg cells active and increase sensitivity of Treg cells to TGF-b.
The surprising finding that IL-6 was able to reduce the positive effect of TGF-b on TbRI expression in T cells provides insights into our understanding of the mechanisms at play in anti-infection immunity and the development of autoimmunity. Since IL-6 is secreted by innate immune cells during infection, it is possible that IL-6 induced by bacterial or viral pathogens suppresses upregulation of TbRI by TGF-b and therefore reduces the threshold of TCR activation. Furthermore, this may help explain why autoimmunity can occur in individuals following infection: IL-6 induced by infection may lower the ability of TGF-b to suppress self-reactive T cells by reducing TbRI expression on T cells and facilitate the differentiation of autoimmune pro-inflammatory T cells. Our findings also raise the possibility that, in addition to promoting expression of IL-23 receptor (Zhou et al., 2008) , IL-6 facilitates Th17 cell generation by restraining TbRI expression. Although mechanistically elusive, it is likely that the NF-kB pathway is also involved: we showed herein that NF-kB negatively regulates TbRI, and IL-6 was previously reported to induce NF-kB activation (Wang et al., 2003) .
Indeed, TCR-mediated NF-kB activation provides a molecular mechanism that links TCR signaling to the regulation of TGF-b signaling. We showed that NF-kB and NFAT inhibitors were both able to suppress the upregulation of IL-2 transcription in stimulated T cells. Nevertheless, only NF-kB inhibitor was able to prevent TbRI downregulation. This finding suggests that the maintenance of TbRI expression by NF-kB inhibitor was not the result of inhibition of T cell activation but was due to specific inhibition of the NF-kB pathway. This is in line with a previous report showing that strong TCR stimulation dampens Treg cell generation through the TCR-CARD11-NF-kB pathway (Molinero et al., 2011) . We have observed direct binding of CARD11 and TbRI proteins in activated T cells (data not shown), suggesting a possibility for post-translational regulation of TbRI by NF-kB. It should be noted that, in addition to the TCR-NF-kBTbRI axis, T cells might employ other mechanisms to regulate TGF-b signaling during T cell activation, such as the TCR-protein kinase Cq pathway (Giroux et al., 2010) . Although SMAD7 has been shown in other cell types to be an inhibitor of TGF-b signaling, it did not play a role in the regulation of TbRI expression during T cell activation. In contrast to previous reports that mainly focused on the inhibitory role of TGF-b signaling in T cell activation, we here reveal that the cross-talk between TGF-b and TCRs is not unidirectional. TCR signals, through NF-kB, reciprocally reduce TGF-b signaling by downregulating TbRI expression. We thus propose a model in which TGF-b signaling is regulated by TCR signals, which in turn controls the switch between T cell quiescence and activation: when T cells encounter weak TCR stimuli such as self-antigens or tumor antigens, TbRI expression allows for TGF-b signaling, which inhibits T cell activation and/or promotes Treg cell generation, further reinforcing T cell quiescence and tolerance. However, when T cells encounter strong TCR stimuli such as pathogens, an adequate T cell response is generated due to reduced sensitivity of activated T cells to TGF-b as a result of TbRI downregulation. In addition, proinflammatory cytokines such as IL-6 may interfere with the balance of T cell quiescence and activation enforced by TGF-b. This may promote antiinfection immunity or trigger the onset of autoimmunity. In sum, this model may provide deeper insights into many fundamental immunology questions, including how naive T cells are kept quiescent and how T cell activation occurs despite the perpetual presence of inhibitory signals.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice C57BL/6, CD45.1 (C57BL/6) and Rag1 À/À mice were purchased from The Jackson Laboratory. DO11.10xRag2
À/À , BALB/c and B10.A mice were obtained from Taconic. Tgfbr2 f/f Esr1-cre and Smad3 À/À mice were previously described (Nakatsukasa et al., 2015; Yang et al., 1999) . Tgfbr1 f/f Esr1-cre mice were generated in house by crossing Esr1-cre mice with Tgfbr1 f/f mice. Smad7
Flow cytometry analysis Intranuclear staining was carried out using the Fixation/Permeabilization buffer solution (eBioscience) according to manufacturer's instruction. For intracellular cytokine staining, cells were stimulated with PMA (50 ng/ml), Ionomycin (250 ng/ml) and Golgi-Plug (1:1000 dilution, BD PharMingen) at 37 C for 3 hr, followed by fixation with the Fixation/Permeabilization buffer solution (BD Biosciences) according to manufacturer's instruction. The staining procedures for MOG 38-49 -specific tetramer were previously described (Kasagi et al., 2014) . Stained cells were analyzed on a LSRFortessa (BD Biosciences) and data was analyzed with FlowJo software.
In vitro T cell activation Naive mouse (CD4 + CD62L + CD44 -) and human (CD4 + CD45RA + ) T cells were purified by magnetic cell sorting (Miltenyi Biotec) and stimulated with indicated concentration of plate-bound anti-CD3 and anti-CD28, with or without addition of various recombinant cytokines at 37 C for the indicated durations. In some experiments, cells were treated with IKK inhibitor VII (1 mM), Cyclosporin A (100 ng/ml) or caffeic acid phenethyl ester (20 mM) for 1 hr before stimulation with anti-CD3 and anti-CD28. Naive 5CC7 T cells were stimulated with irradiated APCs plus 102S, MCC or K5 peptide at 10 ng/ml for 24 hr. Naive OT-I T cells were stimulated with irradiated APCs plus N4, T4 or E1 peptide at either 0.1 or 10 ng/ml for 24 hr.
In vivo T cell activation DO11.10xRag2 À/À mice were treated with either PBS or indicated doses of OVA 323-339 peptide for 24 hr before T cells were analyzed. In adoptive transfer experiments, naive 5CC7.CD45.1 T cells (2 3 10 6 ) were transferred into B10.A mice and the mice were immunized the next day with indicated doses of MCC 88-103 peptide. 5CC7.CD45.1 T cells were purified by flow cytometric cell sorting based on their CD45.1 expression 7 days after the immunization. In some experiments, the recipient B10.A mice were immunized with MCC 88-103 peptide plus CFA (IFA supplemented with 300 mg/mouse M. Tuberculosis) at tail base and 5CC7 T cells in the draining inguinal lymph nodes were harvested for analysis. For the generation of MOG-specific T cells, C57BL/6 mice were immunized with MOG 35-55 peptide (200 mg/mouse) plus either IFA or CFA at tail base. 7 days after pMOG immunization, MOG-specific T cells in the draining inguinal lymph nodes were identified using MOG 38-49 -specific tetramer and purified by flow cytometric cell sorting for analysis.
Isolation of nascent RNA 0.5 mM 5-ethynyl uridine (5-EU) was added into the T cell culture and was incorporated into the cells for 30 min. Total RNA was isolated using RNeasy Mini Kit (QIAGEN) and 5-EU-labeled nascent RNA was captured using Click-iT Nascent RNA Capture Kit (Life Technologies) according to manufacturer's instruction. The captured nascent RNA was then compared with total RNA in real-time PCR.
Analysis of RNA decay during T cell stimulation Naive CD4 + T cells were stimulated with plate-bound anti-CD3 and anti-CD28 for indicated period of time. Cell were washed with PBS and incubated with actinomycin D (10 mg/ml). Total RNA was isolated at discrete time points over a 4 hr period using TRIzol reagent (Invitrogen) to determine mRNA half-life.
ChIP assay
Naive and activated CD4 + T cells (1 3 10 7 ) were prepared for ChIP assay using HighCell# ChIP Kit (Diagenode), according to manufacturer's instruction. Cell lysates were sonicated, followed by precipitation with anti-p50, anti-p52, anti-p65, anti-RelB, anti-cRel, control rabbit IgG or control goat IgG. ChIP DNA was analyzed by real-time PCR using Power SYBR Green PCR Master Mix with the following primers: forward (5 0 -TCTGGAGCTCATTTTGGCGT) and reverse (5 0 -AGCGGGAGCAGTCATAGGTA).
T cell proliferation and Treg cell suppression assays Freshly isolated naive T cells were labeled with CellTrace CFSE according to manufacturer's instruction. CFSE-labeled mouse T cells were stimulated with indicated concentration of anti-CD3 and irradiated APCs or plate-bound anti-CD3 and anti-CD28 (1 mg/ml). CFSE-labeled human T cells were stimulated with indicated concentration of plate-bound anti-CD3 and anti-CD28 (1 mg/ml). After 3 days of culture, dilution of CFSE fluorescence was used to determine cell division. In Treg cell suppression assay, CD4 + CD25 + Treg cells were purified by magnetic cell sorting (Miltenyi Biotec) and cultured with CFSE-labeled CD4 + T cells (Teff), at indicated Treg:Teff ratios, together with irradiated APCs and anti-CD3 (1 mg/ml) for 3 days. Treg cell suppression was determined by the percentage of T cells that were inhibited by Treg cells compared with T cells cultured alone.
TbR retroviral constructs
Expression plasmids for Tgfbr1 and Tgfbr2 were previously described (Yu et al., 2002) . cDNA encoding full-length Tgfr1 and Tgfbr2 were subcloned into pMSCV-IRES-GFP and pMSCV-IRES-Cherry retroviral vectors, respectively. Hek293T cells were transfected with pCL-Eco packaging plasmid and retroviral plasmids using Turbofect (Thermofisher). Retroviral supernatant was harvest 24-48 hr after transfection.
